Presumed ocular histoplasmosis syndrome

Current Opinion in Ophthalmology

Volumn 16, Issue 6, 2005, Pages 364-368

  Prasad, Anita G ^a   Van Gelder, Russell N ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Photodynamic therapy; Presumed ocular histoplasmosis syndrome

Indexed keywords

CORTICOSTEROID;

BLINDNESS; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG EFFICACY; HISTOPLASMA CAPSULATUM; HUMAN; MORBIDITY; OCULAR HISTOPLASMOSIS; PATHOGENESIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA SURGERY; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT INDICATION; TREATMENT OUTCOME;

CHOROIDAL NEOVASCULARIZATION; EYE INFECTIONS, FUNGAL; GLUCOCORTICOIDS; HISTOPLASMA; HISTOPLASMOSIS; HUMANS; PHOTOCHEMOTHERAPY; SYNDROME;

EID: 28444486409     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.icu.0000188321.61101.93     Document Type: Review

References (15)

1. Brown DM, Weingeist TA, Smith RE. Histoplasmosis. In: Pepose, JS, Holland GN, Wilhelmus KR, editors. Ocular infection and immunity. St. Louis, MO: Mosby; 1996.
2. Hawkins BS, Alexander J, Schachat AP. Ocular histoplasmosis. In: Ryan, SJ, Schahchat, AP, editors. Retina. St. Louis, MO: Mosby; 2001.
3. Ongkosuwito JV, Kortbeek LM, Van der Lelij A, et al. Aetiological study of the presumed ocular histoplasmosis syndrome in the Netherlands. Br J Ophthalmol 1999; 83:535-539.
4. Spencer WH, Chan C, Shen DF, Rao NA. Detection of Histoplasma capsulatum DNA in lesions of chronic ocular histoplasmosis syndrome. Arch Ophthalmol 2003; 121:1551-1555.
5. Macular Photocoagulation Study Group. Krypton laser photocoagulation for neovascular lesions of ocular histoplasmosis: results of a randomized clinical trial. Arch Ophthalmol 1987; 105:1499-1507.
6. Shah GK, Blinder KJ, Hariprasad SM, et al. Photodynamic therapy forjuxta-foveal choroidal neovascularization due to ocular histoplasmosis syndrome. Retina 2005; 25:26-32. The authors retrospectively review 23 eyes of 23 patients treated with photo-dynamic therapy for presumed ocular histoplasmosis syndrome and find improvement of 3 or more lines in 30% of eyes and stabilization in another 52%.
7. Liu JC, Boldt HC, Folk JC, Gehrs KM. Photodynamic therapy of subfoveal and juxtafoveal choroidal neovascularization in ocular histoplasmosis syndrome: a retrospective case series. Retina 2004; 24:863-870.
8. Busquets MA, Shah GK, Wickens J, et al. Ocular photodynamic therapy with verteporfin for choroidal neovascularization secondary to ocular histoplasmosis syndrome. Retina 2003; 23:299-306.
9. Rosenfeld PJ, Saperstein DA, Bressler NM, et al. Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study. Ophthalmology 2004; 111:1 725-1 733. Prospective open-label study of 22 patients with choroidal neovascularization from presumed ocular histoplasmosis syndrome showing a 7 letter improvement in vision in 45% of patients and 8 letter or more loss in 18%, along with angiographie stabilization in 85%.
10. Submacular Surgery Trials Research Group. Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic. Arch Ophthalmol 2004; 122:1597-1611. Large, well-controlled 225 patient prospective randomized clinical trial comparing submacular surgery to natural history for choroidal neovascular membrane (CNVM) secondary to presumed ocular histoplasmosis syndrome. At the 24-month examination, no significant difference in successful outcome was seen between surgery and observation groups; CNVM recurred in 58% of surgically treated eyes. A slight benefit for surgery was seen in those patients initially seen with 20/100 or worse vision. No comparison to photodynamic therapy was performed in this study, however.
11. Rechtman E, Allen VD, Danis RP, et al. Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome. Am J Ophthalmol 2003; 136:739-741.
12. Holekamp NM, Thomas MA, Pearson A. The safety profile of long-term, high-dose intraocular corticosteroid delivery. Am J Ophthalmol 2005; 139:421-428.
13. Edwards AO, Ritter R, Abel KJ, et al. Complement factor H polymorphism and age-related macular degeneration. Science 2005; 308:421-424. See annotation for reference 15.
14. Haines JL, Hauser MA, Schmidt S, et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 2005; 308:419-421. See annotation for reference 15.
15. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005; 308:385-389. Three landmark studies performing genome-wide screens of susceptibility loci for macular degeneration. All three studies showed nearly identical 7-fold increased disease likelihood for individuals carrying a histidine (as opposed to tyrosine) residue at amino acid 402 of complement factor H. These studies clearly suggest an inflammatory mechanism to age-related macular degeneration.